Private equity buyouts have effectively become a third major exit route for software companies as IPOs and M&A slow, according to venture capitalist David Sacks.
“Historically we only had two good exits for software businesses,” Sacks said on the “All-In Podcast” released on April 24. “One was IPO, the other was M&A. And then these big private equity shops came along and gave us a third potential exit.”
That third path, selling to private equity firms using heavy debt, is gaining traction as traditional exits cool and AI reshapes SaaS economics, said Sacks.
Don’t Miss:
Public Software Rout Sets The Backdrop
Sacks made the comments during a sharp downturn in public software stocks.
The podcast discussion was partly driven by concerns around Medallia, a Thoma Bravo-backed company reportedly struggling, with sales teams missing targets.
Sacks pointed to a deeper shift as enterprises replace vertical software-as-a service tools with internally built AI solutions. “Agents have become so good and so fast and so cheap that many enterprises can simply spin up an alternative to a vertical SaaS solution,” he said. “That’s crushing the sales team’s ability to sell in.”
This is weakening the predictable recurring revenue that has long been central to SaaS business models.
Trending: Deloitte’s #1 Fastest-Growing Software Company Lets Users Earn Money Just by Scrolling — Investors Can Still Get In at $0.50/Share
Why Debt-Fueled Buyouts Are Under Pressure
Private equity deals typically rely on stable cash flows and are often structured with roughly one-third equity and two-thirds debt. “It was believed for a long time that software did have those predictable cash flows, at least for the mature businesses,” Sacks said on the podcast.
That assumption is now being tested. Declines in net revenue retention, in some cases from over 120% to 80%, are challenging the ability of leveraged companies to service debt, he said.
Sacks sees both opportunity and risk.
Public valuations have dropped sharply. The median enterprise value-to-revenue multiple now stands at 3.4x as of March, down significantly from peaks above 18x in 2021, according to Adventis Advisors. “You can buy a dollar for 50 cents,” Sacks said.
But rapid AI disruption could challenge the traditional private equity playbook, which often depends on executing operational improvements over a multiyear holding period.
See Also: Traders Are Flocking to Direxion ETFs — Targeting Tesla and Elon Musk’s Market Moves
A Lifeline For Founders With New Realities
For founders and venture investors, private equity can offer a fallback as IPO and M&A windows remain constrained, Sacks said.
Such deals, however, are likely to involve tighter assumptions, more hands-on operations and less reliance on financial engineering, he said.
From SaaS Slowdown To Broader Growth
Sacks framed the SaaS struggles as part of a broader economic transition on the “All-In Podcast,” citing Federal Reserve Chair nominee Kevin Warsh’s comments about AI’s deflationary impact during his confirmation hearing on April 21.
While AI is pressuring software incumbents, Sacks said it is also freeing up capital for businesses. Companies that cut their SaaS spending can redeploy those savings into other areas of growth, he added.
Read Next: Become a futures trading pro, without spending any money – why Plus500 is the top choice for beginner investors
AI Disruption and Market Compression Are Forcing Investors to Reassess Long-Term Strategy
As software valuations continue to reset and AI reshapes how companies build and monetize products, investors are being forced to rethink assumptions that held up for much of the past decade. The shift away from predictable SaaS growth and traditional IPO exits toward more complex capital structures is making it harder to rely on old playbooks.
Building Wealth Across More Than Just the Market
Connect Invest
Mode Mobile
rHealth
rHealth is building a space-tested diagnostics platform designed to bring lab-quality blood testing closer to patients in minutes rather than weeks. Originally validated in collaboration with NASA for use aboard the International Space Station, the technology is now being adapted for at-home and point-of-care settings to address widespread delays in diagnostic access.
Backed by institutions including NASA and the NIH, rHealth is targeting the large global diagnostics market with a multi-test platform and a model built around devices, consumables, and software. With FDA registration in progress, the company is positioning itself as a potential shift toward faster, more decentralized healthcare testing.
Direxion
Immersed
Arrived
Masterworks
Public
AdviserMatch
Accredited Debt Relief
Finance Advisors
Image: Shutterstock